香港六合彩中特网

XClose

EGA Institute for Women's Health

Home
Menu

In utero stem cell transplantation

Overview:听Osteogenesis imperfecta (OI) is an inherited genetic disease characterised by brittle bones. When severe, babies present in the womb with fractures that can be seen on ultrasound scan. Patients with severe OI have repeated, multiple fractures through life, pain and handicap. There is no cure and current treatment is palliative. Fetal therapy using stem cells presents an opportunity. Transplantation before birth at the onset of disease may give better engraftment with less rejection than transplantation after birth. Mesenchymal stem cells (MSC) are promising candidates with minimal cancer risk.

Our aim is to develop prenatal and postnatal transplantation of MSC as a therapy for severe types of OI.

Design:听We are conducting a multicentre case control study of MSC transplantation in severe types of OI (types II/III, severe type IV). We will compare prenatal (in utero) and postnatal transplantation and evaluate safety and efficacy outcomes (fracture frequency and growth). The multicentre study is lead by Sweden, with three other clinical centres at 香港六合彩中特网, Koln in Germany, and Leiden in The Netherlands. We are also working with Great Ormond Street Hospital to develop non-invasive prenatal testing for OI.

Osteogenesis Imperfecta

Team:听,听,听听(香港六合彩中特网 Royal Free Biobank),听听(Institute of Child Health),听听(Great Ormond Street Hospital).

Funding:听鈥淪tem cell therapy to treat severe osteogenesis imperfecta鈥. Swedish Krona 16,500,000 (拢1,357,887) over 3 years. Funded by a 鈥淔ramework grant in clinical therapy research鈥 from Swedish Research Council. Collaboration with Dr Cecilia G枚therstr枚m and听.

Links:听